FDA issues warning over Celebrex, Bextra ads

Share this article:
The FDA has issued a warning letter to Pfizer stating that television and print ads for its painkillers Celebrex and Bextra are misleading to consumers.
A total of five advertisements failed to disclose side effects and other risk information and made "unsubstantiated effectiveness claims," the letter posted on the FDA's Web site Wednesday said.
A company spokeswoman told Reuters the Celebrex ads cited in the letter were no longer running. The spokeswoman had no comment on the other materials including a Bextra patient brochure and a television infomercial.
Pfizer said in a Reuters report it would discuss its next steps with the FDA. The letter gives Pfizer until Jan. 26 to respond.
On Dec. 17, the National Institutes of Health halted a cancer trial using Celebrex after researchers discovered an increased risk of heart attack.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.